Please login to the form below

Not currently logged in
Email:
Password:

Allergan veteran joins Kala as head of business development

Charles McDermott has experience in ophthalmology

Kala Pharma Charles McDermott Charles McDermott, who has spent the last eight years at Allergan, has joined serious disease specialist Kala Pharmaceuticals as executive VP, business development.

McDermott was most recently VP, business development at Botox developers Allergan, and during his time at the company he completed several transaction and partnership agreements involving such products as eye inflammation treatments Acular and Acuvail, as well as Latisse to support the growth of eyelashes.

Prior to joining Allergan, McDermott spent several years at deCODE Genetics in several buinsess development positions.

He also has research experience, serving as a research scientist at Agouron Pharmaceuticals.

Kala will benefit from McDermott's experience in eye conditions as the company looks to advance its lead ophthalmic candidates towards clinical studies.

“We are rapidly gaining momentum within the ophthalmic industry and Charlie shares our vision to make a difference in the lives of patients suffering from ocular diseases,” said Dr Guillaume Pfefer, CEO of Kala.

“Based on his experience at Allergan, he fully appreciates the potential of Kala's mucosal penetrating product technology to transform clinical practice and to enable effective local treatments for serious diseases,” he added.

30th May 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics